Compare Davita Inc (DVA) vs Direxion Daily S&P 500 Bull 3X Shares (SPXL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Davita Inc vs Direxion Daily S&P 500 Bull 3X Shares — how do they compare? Davita Inc trades at $179.97 (market cap $11.38B), while Direxion Daily S&P 500 Bull 3X Shares trades at $295.75. The key difference: Direxion Daily S&P 500 Bull 3X Shares is trading nearer its 52-week high, Davita Inc nearer its low. Which is the better fit depends on your goals.
| DVA | SPXL | |
|---|---|---|
Market Cap | $11.38B | — |
Sector | Health | Leveraged / Inverse |
52-Week High | $240.96 | $296.39 |
52-Week Low | $103.87 | $170.20 |
Enterprise Value | $24.10B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DaVita (DVA) trades at $180.25, down 1.87% amid mixed signals. The stock shows strong earnings momentum with three consecutive quarterly beats (Q4 2025-Q2 2026) but faces margin pressure. Technical indicators are conflicted with a bullish overall signal but bearish moving averages. Revenue growth remains steady, climbing from $11.6B in 2022 to $13.6B in 2025, though net income margin fluctuated between 4.82% and 7.3% over the same period.
The outlook is cautiously optimistic with a $232.25 consensus price target offering 29% upside. Key risks include reimbursement pressure and high debt levels (debt-to-asset ratio of 65.55% in 2025). Analyst sentiment leans neutral (56.52% Hold) despite recent earnings strength, reflecting concerns about payer mix and margin sustainability.
SPXL trades at $295.71, down 0.16% with a bullish technical outlook supported by moving averages. The stock shows strong momentum indicators with ADX signaling trend strength while RSI levels suggest potential overbought conditions. Recent news highlights S&P 500 reaching record highs with JPMorgan raising its 2026 target to 8,000, citing AI-driven earnings strength and corporate performance.
The leveraged ETF benefits from strong market momentum but faces valuation concerns with the S&P 500 at historically high Shiller P/E ratios. Key risks include market volatility ahead of inflation reports and potential profit-taking near resistance levels. The AI investment theme provides growth catalysts, though elevated valuations warrant caution for new positions.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Davita Inc
DaVita is the largest provider of dialysis services in the United States, boasting market share that eclipses 35% when measured by both patients and clinics. The firm operates over 3,100 facilities worldwide, mostly in the U.S., and treats over 240,000 patients globally each year. Government payers dominate U.S. dialysis reimbursement. DaVita receives approximately 69% of U.S. sales at government (primarily Medicare) reimbursement rates, with the remaining 31% coming from commercial insurers. However, while commercial insurers represented only about 10% of the U.S. patients treated, they represent nearly all of the profits generated by DaVita in the U.S. dialysis business.
Read more on DVA →About Direxion Daily S&P 500 Bull 3X Shares
SPXL aims for 300% of the S&P 500's daily performance. It uses swaps and futures to provide 3x leverage, making it a high-risk tool for short-term traders. Due to daily resets, it is prone to volatility decay and is not intended for long-term holding.
Read more on SPXL →
